
Musk testified in federal court in California on Wednesday in his lawsuit against OpenAI, alleging that Sam Altman and co-founders 'stole a charity' by transitioning the nonprofit into a for-profit structure. Under cross-examination, he stated that Tesla's AI work is focused only on self-driving and not AGI (artificial general intelligence, AI systems that can perform any intellectual task a human can), directly contradicting a recent post claiming 'Tesla will be one of the companies to make AGI.'
Musk's case rests partly on the argument that OpenAI's transition to a traditional corporation is dangerous because it reduces focus on safety. The court also allowed questioning about whether xAI and OpenAI's approaches to safety differ, though Judge Yvonne Gonzalez Rogers ruled out testimony about scandals caused by specific AI models.
Musk testified he had discussed converting OpenAI to a for-profit as early as 2016 and in 2017 explored creating a for-profit arm where he would hold majority equity. He also claimed he invested $100 million in OpenAI, though he later acknowledged that $38 million actually changed hands, arguing his reputation and network made up the difference.
Summaries like this, every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
The Rhode Island Small Business Development Center and Meta are hosting a free, hands-on AI workshop on Decemb…

A Seeking Alpha analyst upgraded Broadcom (AVGO) to Strong Buy, arguing it should lead investors out of the cu…

Merck has signed an AI-related deal, one of several pharma items in a news roundup that also covers China and…

Visa is developing agentic commerce infrastructure that would let AI agents shop and pay on behalf of consumer…

On the Nov. 19 earnings call, CEO John Furner said U.S

Merck announced a research collaboration with Isomorphic Labs to discover small-molecule candidates against an…
